BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 23083111)

  • 1. Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections.
    Scott LJ
    Drugs; 2012 Nov; 72(16):2141-65. PubMed ID: 23083111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Micafungin: a review of its use in adults for the treatment of invasive and oesophageal candidiasis, and as prophylaxis against Candida infections.
    Cross SA; Scott LJ
    Drugs; 2008; 68(15):2225-55. PubMed ID: 18840009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Micafungin: A Review in the Prophylaxis and Treatment of Invasive Candida Infections in Paediatric Patients.
    Scott LJ
    Paediatr Drugs; 2017 Feb; 19(1):81-90. PubMed ID: 28083856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
    Moen MD; Lyseng-Williamson KA; Scott LJ
    Drugs; 2009; 69(3):361-92. PubMed ID: 19275278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections in pediatric patients.
    Carter NJ; Keating GM
    Paediatr Drugs; 2009; 11(4):271-91. PubMed ID: 19566111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Echinocandin antifungal drugs in fungal infections: a comparison.
    Chen SC; Slavin MA; Sorrell TC
    Drugs; 2011 Jan; 71(1):11-41. PubMed ID: 21175238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Micafungin in invasive candidiasis among oncohematological patients].
    Jarque I; Angel Sanz M
    Rev Iberoam Micol; 2009 Mar; 26(1):75-7. PubMed ID: 19463282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program.
    Pfaller MA; Messer SA; Rhomberg PR; Castanheira M
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28052853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis.
    Keating G; Figgitt D
    Drugs; 2003; 63(20):2235-63. PubMed ID: 14498760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literature.
    Kofla G; Ruhnke M
    Eur J Med Res; 2011 Apr; 16(4):159-66. PubMed ID: 21486730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Scientific evidence supporting the use of micafungin in the treatment of invasive candidiasis].
    Montejo M; Quindós G
    Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():15-22. PubMed ID: 21420572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The echinocandins: three useful choices or three too many?
    Bal AM
    Int J Antimicrob Agents; 2010 Jan; 35(1):13-8. PubMed ID: 19942413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Micafungin - the newest echinocandin.
    Temesgen Z; Barreto J; Vento S
    Drugs Today (Barc); 2009 Jun; 45(6):469-78. PubMed ID: 19856528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Micafungin.
    Jarvis B; Figgitt DP; Scott LJ
    Drugs; 2004; 64(9):969-82; discussion 983-4. PubMed ID: 15101786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.
    Pfaller MA; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ
    J Clin Microbiol; 2008 Jan; 46(1):150-6. PubMed ID: 18032613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Echinocandins: the newest class of antifungals.
    Sucher AJ; Chahine EB; Balcer HE
    Ann Pharmacother; 2009 Oct; 43(10):1647-57. PubMed ID: 19724014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biofilm Production and Antibiofilm Activity of Echinocandins and Liposomal Amphotericin B in Echinocandin-Resistant Yeast Species.
    Marcos-Zambrano LJ; Gómez-Perosanz M; Escribano P; Zaragoza O; Bouza E; Guinea J
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3579-86. PubMed ID: 27021323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations.
    Arendrup MC; Perlin DS; Jensen RH; Howard SJ; Goodwin J; Hope W
    Antimicrob Agents Chemother; 2012 May; 56(5):2435-42. PubMed ID: 22354305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Micafungin sodium, the second of the echinocandin class of antifungals: theory and practice.
    Vehreschild JJ; Cornely OA
    Future Microbiol; 2006 Aug; 1(2):161-70. PubMed ID: 17661660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.